Previously, we discussed in this chapter how you move your main points in a logical way. In this section, you will provide a number of organizational models that will allow you to create a logically organized language. The first organizational model we are discussing is categorical/current. Methods: A scientific committee has selected clinically relevant questions regarding the efficacy and safety of active ingredients and phototherapy in psoriasis. This selection was made with the Delphi method. Systematic literary research was conducted at Medline, Embase and Cochrane Library. The articles selected for analysis were verified and the amount of evidence was assessed in accordance with Oxford`s independence levels. A meeting of experts was held in June 2011, with the participation of 42 dermatologists. Recommendations for the use of topical treatments and phototherapy were made in interactive workshops where evidence was presented and discussed. The agreement between the participants was evaluated on a 10-point scale. Participants systematically assessed the impact of the recommendations on clinical practice. Under the terms of the agreement, Apricus is entitled to obtain up to $3.8 million from Recordati in the form of pre-mortgage and pre-auction milestone payments. Apricus is also entitled to obtain up to $47 million in one-stage sales payments, plus double-digit royalties, based on net sales of the product in Recordati`s territory.
In return, Recordati has the exclusive right to: Vitaros® on the territory comprising a number of countries and regions, including Spain, Russia, Turkey, Ireland, Portugal, Greece, Cyprus, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Ukraine, Georgia and some African countries. Recordati has agreed to obtain all necessary administrative authorizations at its own expense. The common goal is to introduce innovative products for topical treatments into the rapidly expanding global medical cannabis market. According to a report by the IMARC Group, the global medical cannabis market is expected to reach $44 billion by 2024. „We are impressed by Cannassures` high standards and the progressive approach to business development in the field of medical cannabis. For Lipidor, the agreement with Cannassure has considerable commercial potential and we will return based on the results of the feasibility study with more details on the size of this great opportunity,“ says Ola Holmlund, CEO of Lipidor Vitaros® is authorized for the treatment of ED by a number of European health authorities and Health Canada. Vitaros® is a cream formulation of Alprostadil, a vasodilator, combined with our proprietary DDAIP permeation amplifier. HCl, which directly increases blood flow in the penis, leading to an erection.